undruggable target

FDA Approves First Direct RAS Inhibitor, Doubling Survival in Pancreatic Cancer and Cracking Oncology’s ‘Undruggable’ Target

The Food and Drug Administration on Wednesday approved Rasonque (daraxonrasib), a once-daily pill from Revolution Medicines that directly inhibits multiple…

Read More »